Homocysteine lowering interventions for preventing cardiovascular events.

ABSTRACT:

Background

Cardiovascular disease such as coronary artery disease, stroke and congestive heart failure, is a leading cause of death worldwide. A postulated risk factor is elevated circulating total homocysteine (tHcy) levels which is influenced mainly by blood levels of cyanocobalamin (vitamin B12), folic acid (vitamin B9) and pyridoxine (vitamin B6). There is uncertainty regarding the strength of association between tHcy and the risk of cardiovascular disease.

Objectives

To assess the clinical effectiveness of homocysteine-lowering interventions (HLI) in people with or without pre-existing cardiovascular disease.

Search strategy

We searched The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (issue 3 2008), MEDLINE (1950 to August 200

SUBMITTER: Marti-Carvajal AJ 

PROVIDER: S-EPMC4164174 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature